

ERRATUM

Open Access



# Erratum to: Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer

Jianguang Qiu<sup>1†</sup>, Shubin Peng<sup>2†</sup>, Jie Si-Tu<sup>1</sup>, Cheng Hu<sup>1</sup>, Wentao Huang<sup>1</sup>, Yunhua Mao<sup>1</sup>, Wenhan Qiu<sup>1</sup>, Ke Li<sup>1\*</sup> and Dejuan Wang<sup>1\*</sup>

## Erratum

After publication of the original article [1] the authors found that the case number “n” had been incorrectly marked for each Gleason group in Figure 1g (Fig. 1g).

The biopsy Gleason group information had been used in the original article:

BPH: n=30

GS≤6: n=25

GS=7: n=13

GS≥8: n=12

Data should instead have been taken from the post-operative Gleason group, and the figures should therefore appear as the following in Figure 1g:

BPH: n=30

GS≤6: n=22

GS=7: n=10

GS≥8: n=18

A corrected, full version of Figure 1 with the above amendments has been included in this Erratum.

Corrected Figure 1

## Author details

<sup>1</sup>Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China. <sup>2</sup>Department of Urology and Liver Disease Laboratory, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Received: 1 August 2017 Accepted: 1 August 2017

Published online: 24 August 2017


## Reference

1. Qiu J, Peng S, Si-Tu J, Hu C, Huang W, Mao Y, Qui W, Li K, Wang D. Identification of endonuclease domain-containing 1 as a novel tumor suppressor in prostate cancer. BMC Cancer. 2017;17:360. doi:10.1186/s12885-017-3330-5.

\* Correspondence: maoyh@mail2.sysu.edu.cn; sasaer@126.com

<sup>†</sup>Equal contributors

<sup>1</sup>Department of Urology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China



**Fig. 1** ENDOD1 is downregulated in PCa tissues with high Gleason scores. **a-f** Representative images showed the ENDOD1 immunostaining intensity. BPH tissues showed negative (**a**) and moderate (**b**) ENDOD1 staining. PCa tissues showed negative (**c**), strong (**d**), and moderate (**e**) and weak (**f**) ENDOD1 staining, respectively. Magnification 200x. **g**. Immunoreactivity scores (IRS) analysis of ENDOD1 in BPH tissues and PCa tissues. IRS were determined by multiplying the level of staining intensity (negative = 0, weak = 1, moderate = 2, strong = 3) and percentage of positively stained cells (0% = 0, <10% = 1, 11–50% = 2, 51–80% = 3, >80% = 4). Results indicated that PCa tissues with higher Gleason scores (Gleason score ≥ 7) showed significantly lower ENDOD1 expression than that with low Gleason score and BPH tissues. \**P*<0.05; \*\**P*<0.01